Pharma Focus Asia

Hi-Tech Pharmaceuticals Forms Joint Venture with Chinese Conglomerate

Friday, May 12, 2017

Hi-Tech Pharmaceuticals, Inc. and Shanghai Yongyi Biotechnology Co., Ltd. announce the signing of an agreement for the creation of a joint venture called Yongyi Hi-Tech Nutraceuticals. The company's mission is to develop the market for innovative nutritional supplements on a global basis. The aim of such dietary supplements, the results of decades of research efforts, is to improve people's quality of life, improve their physique, and manage weight by supplying nutrients essential to their physiology.

Yongyi Hi-Tech Nutraceuticals products will benefit from both Shanghai Yongyi's nutritional research and Hi-Tech's bioavailability research. The partnership represents the first time that the raw material producer and a finished goods manufacturer have joined together to enter this fast-growing market.

Yongyi Hi-Tech Nutraceuticals based in Pennsylvania will feature Hi-Tech's innovative, proprietary Cyclosome® technology and its high absorption ingredients at several upcoming trade shows throughout the United States.

Hi-Tech's proprietary Cyclosome® Technology are first complexed or bonded — cyclodextrins are hydrophobic on the inside but hydrophilic (water-loving) on the outside. This means that they can be complexed with hydrophobic compounds (ie hormones) – and since they're large, the hydrophobic compound can literally fit inside them. Once the cyclodextrin complex is formed we then encase or wrap a liposome around the cyclodextrin complex which is made of a high purity phosphatidylcholine and phytosterol matrix. You can think of all this in terms of a 'Trojan Horse,' passing through the liver unharmed and intact. As opposed to being destroyed in the liver like all other hormonal products on the market, past and present. This new Cyclosome® technology allows the 'Trojan Horse' to deliver many low bioavailable plant extracts, prohormones and other poorly absorbed nutraceuticals to the systemic circulation by the intestinal lymphatic route, circumventing first-pass inactivation in the liver for the very first time. Almost all previous Oral capsules and tablets manufactured to increase testosterone — including Testosterone itself — are involved in the "first pass affect" which renders the active compounds virtually useless.

Yongyi Hi-Tech Nutraceuticals believes manufacturers looking to create better absorbable products should focus particular emphasis on our Cyclosome® highly bioavailable CoQ10 formulation for either tablets, capsules, soft gels or liquid supplements. The superior bioavailability versus conventional CoQ10 has been proven in a large bioavailability study conducted with CoQ10. We also believe our Cyclosome® highly bioavailable α-lipoic acid weight loss and weight management ingredient will be featured as well.

Yongyi Hi-Tech Nutraceuticals is convinced that the bioavailability of dietary ingredients will enjoy increasing importance and significance in the dietary supplement industry as more and more consumers are educated and understand that only an active that is sufficiently absorbed in the body will achieve the desired results or efficacy. We will have a complete line of ingredients utilizing our Cyclosome® technology such as: Tumeric/Curcumin, Milk Thistle, Chrysin, DHEA, Boswelia, Green Tea, Gingko Biloba, Ginseng, Grape seed, Huperzine A, Resveratrol, Tribulus Terrestris, Dioscorea, and Vitamin C to name a few.

Yongyi Hi-Tech Nutraceuticals is on the verge of signing a licensing and distribution agreement with a large US raw material distributor for its cholesterol-lowering ingredient, CholedreneTM. Under the terms of the licensing agreement, the US distributor to be named later will supply CholedreneTM for distribution to dietary supplement manufacturers. These manufacturers are expected to incorporate the ingredient into a variety of cholesterol-lowering supplements to be sold in natural health food stores across the United States.

"Yongyi Hi-Tech Nutraceuticals is a supplier of natural supplement ingredients targeting large demographic categories," said Brandon Schopp, Vice President of Sales at Hi-Tech. "The importance of cholesterol management is growing annually in light of new research concerning the cardiovascular benefit of lowering cholesterol. CholedreneTM has the ability to lower levels beyond levels previously recommended by most physicians. A clinically proven, proprietary ingredient, such as CholedreneTM  is clearly a much sought after product and carries a distinct advantage when targeting this burgeoning cholesterol-lowering market."

Yongyi Hi-Tech Nutraceuticals is proud to announce that its state-of-the-art Red Yeast Rice extraction technology found in CholedreneTM  is the latest in a series of innovations coming to market by Yongyi Hi-Tech Nutraceuticals which enables manufacturers of supplement and functional beverages to include high quality yet cost-effective natural ingredients into their products. This new extraction method for Monacolins allows the biotechnology company to produce natural Red Yeast Rice at purities of up to 5% — far exceeding that of the industry standard. The new process is also optimized for a higher yield, which reduces the unit cost of production therefore making it easier (and cheaper) than ever for companies to include this wonderful natural ingredient into the dietary supplements and functional beverages.

The state-of-the-art technologies employed in this innovative extraction process include: Superfiltration, Electrodialysis, and Vacuum Concentration. Superfiltration uses ceramic filters with nano-scale pores to filter out large molecular contaminants from the earlier red yeast rice tea extraction process. Electrodialysis uses an applied electric current and membrane to remove any traces of inorganic salts present in the extraction solution. Vacuum Concentration promotes the evaporation of our water solvent and ensures that the final extract is obtained with the highest possible yield. The combination of the three technologies optimizes the production of an ultra-pure, yet economical extract that is suitable for direct incorporation into supplements and beverages.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024